ISSN 2282-0930 • Epidemiology Biostatistics and Public Health - 2026, Volume 21, Issue 1

GLP-1 Receptor Agonists and Substance Use Disorders: A Public Health Opportunity with Emerging Safety Concerns

Silvia Martinelli[(1)], *Niccolò Petrucciani*[(2)]

(1) Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy (ROR: https://ror.org/03h7r5v07)
(2) Department of Medical and Surgical Sciences and Translational Medicine, Division of General and Hepatobiliary Surgery, St. Andrea Hospital, Sapienza University of Rome, Italy (ROR: https://ror.org/02be6w209)

CORRESPONDING AUTHOR: Silvia Martinelli, Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy. Email: silvia.martinelli04@icatt.it, Tel: 00393393474716

Keywords: GLP-1 receptor agonists; Substance use disorders; Pharmacovigilance; Psychiatric safety; Public health; Behavioral pharmacotherapy

According to the Global Burden of Disease Study (GBD), mental and substance use disorders accounted for approximately 183.9 million disability-adjusted life years (DALYs) worldwide in 2010, representing 7.4% of all global DALYs. Within this group, illicit drug use disorders alone were responsible for an estimated 20 million DALYs [1]. SUDs are also strongly associated with years lived with disability (YLDs): together with mental disorders, they account for approximately 22.9% of all global YLDs [2]. This highlights the chronic and debilitating nature of these conditions, and the considerable strain they place on healthcare systems and social structures. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have significantly improved metabolic outcomes in patients with obesity and type 2 diabetes [3]. Beyond their established role, emerging evidence suggests potential efficacy in addressing substance use disorders (SUDs) and behavioral addictions [4,5]. This intersects critically with public health priorities, given the high global burden of both obesity and SUDs, often co-occurring in vulnerable populations.

Preclinical studies indicate that GLP-1RAs modulate dopaminergic reward pathways, attenuating craving, compulsive use, and withdrawal-related behaviors [6,7]. Observational data further suggest reduced rates of alcohol intoxication and opioid overdose in patients treated with GLP-1RAs [8,9]. These findings offer promising avenues for integrated care strategies targeting metabolic and addictive comorbidities. However, recent population-based studies raise concerns regarding psychiatric safety. GLP-1RA use has been associated with increased risks of depression, anxiety, and suicidal behavior, particularly in patients with rapid weight loss or pre-existing psychological vulnerabilities [10]. While causality remains to be confirmed, such findings necessitate caution in off-label or experimental use. From a public health perspective, the potential expansion of GLP-1RAs to populations with SUDs underscores the need for: (i) targeted pharmacovigilance, (ii) risk-benefit assessments in diverse demographic groups, and (iii) [11] integration of mental health screening into treatment protocols. Furthermore, anecdotal reports and pharmacosurveillance data have noted rising instances of misuse and non-medical use, particularly of semaglutide [12].

In conclusion, while GLP-1RAs represent a novel and potentially transformative tool in managing SUDs and associated comorbidities, robust epidemiological evidence and continuous safety monitoring must guide their implementation. Public health systems should prioritize real-world data collection and long-term outcome evaluation before widespread adoption in this context.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

DOI: 10.54103/2282-0930/29800
Accepted: 11th September 2025

© 2026 Daly et al

FUNDING

No specific funding was received for this communication.

REFERENCES

1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013 Nov 9;382(9904):1575-86.
2. Onaemo VN, Chireh B, Fawehinmi TO, D'Arcy C. Comorbid substance use disorder, major depression, and associated disability in a nationally representative sample. J Affect Disord. 2024 Mar 1;348:8-16.
3. Ahrén B. Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy. Endocrinology. 2023 Nov 2;164(12):bqad166.
4. Hong CT, Chen JH, Hu CJ. Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease. J Biomed Sci. 2024 Nov 5;31(1):102.
5. Martinelli S, Petrucciani N, Regazzi L, Gualano MR. Bariatric Surgery and New-Onset Substance Use Disorders: A Systematic review and Meta-analysis. Obes Surg. 2024 Apr;34(4):1366–75.
6. Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2020;14:614884.
7. Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023;14:1063033.
8. Lee S, Li M, Le GH, Teopiz KM, Vinberg M, Ho R, et al. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review. Ann Gen Psychiatry. 2024 Nov 11;23(1):45.
9. Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2024 Oct 16;
10. Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024 Oct 18;14(1):24433.
11. Martinelli S, Mazzotta A, Longaroni M, Petrucciani N. Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug Alcohol Depend. 2024 Nov 1;264:112424.
12. du Soulier N, Pariente A, Bezin J, Grenet G, Faillie JL, de Germay S. Use and Potential Misuse of Glucagon-Like Peptide-1 Receptor Agonists in France: A Nationwide Cohort Study. Value Health. 2025 Jun 23:S1098-3015(25)02404-0.